For years, the healthcare industry relied on the Asthma Medication Ratio (AMR) as the gold standard for tracking how well patients managed their respiratory health. By comparing controller medications to total asthma medications, the AMR sought to gauge adherence and control. However, as of measurement year 2026, the National Committee for Quality Assurance (NCQA) has officially retired this metric.
In its place comes a more actionable, outcomes-oriented standard: the "Follow-Up After Acute and Urgent Care Visits for Asthma" (AAF-E). While this shift represents a long-overdue evolution in how we measure quality, it highlights a critical reality: simply recording a follow-up visit is not the same as providing effective care. For patients, clinicians, and health plans, the transition from the AMR to the AAF-E is a call to move beyond administrative box-checking and toward deep, diagnostic, and preventative intervention.
The Evolution of Quality: From Medication Ratios to Clinical Outcomes
The AMR was inherently limited by its reliance on a proxy for persistent asthma. It failed to account for patients with intermittent asthma—individuals who might feel healthy for months, only to find themselves gasping for air in an emergency department (ED) or urgent care center. Because the AMR focused on dispensing patterns, it ignored the reality that a patient’s actual disease burden is often dictated by environmental triggers and acute exacerbations rather than daily medication possession.
The new AAF-E measure tracks the percentage of patients—aged 5 to 64—who, following an acute or urgent care visit, an ED encounter, an observation stay, or an inpatient admission, receive an outpatient follow-up visit with an asthma-related diagnosis within 30 days. This shift moves the focus from pharmacy claims (what the patient has in their cabinet) to clinical engagement (what the patient does after a crisis).
A Chronology of Asthma Care Challenges
To understand why this change is necessary, one must look at the historical trajectory of asthma management in the United States.
- The Era of Reactive Care: Throughout the 2000s and 2010s, the focus remained largely on symptomatic relief and episodic care. Despite the publication of standardized guidelines by the National Asthma Education and Prevention Program (NAEPP), implementation remained fragmented.
- The 2020 Pivot: The 2020 NAEPP guideline update served as a watershed moment, emphasizing the importance of personalized, trigger-aware treatment plans. It underscored that asthma is not a one-size-fits-all condition.
- The 2022-2025 Data Realization: Recent data revealed that 42.4% of asthma patients suffered at least one exacerbation in 2022. During the same period, NCQA claims analyses demonstrated that follow-up rates post-ED visit were dismal: 46.1% for commercial populations and a startling 33.9% for Medicaid beneficiaries.
- 2026 and Beyond: The retirement of the AMR and the birth of AAF-E signify an institutional acknowledgment that the primary barrier to better asthma outcomes is not just access to medication, but the lack of coordinated care following an acute event.
Supporting Data: The High Cost of the "Next Exacerbation"
The urgency of this transition is supported by compelling data regarding the predictability of asthma attacks. A recent exacerbation is consistently identified as the single strongest predictor of the next one.
In a cohort of patients with severe or difficult-to-treat asthma, individuals 12 and older who experienced an ED visit or hospitalization in the prior three months were six times more likely to face a future severe exacerbation over an 18-month period. For children, the news is equally sobering; a systematic review of over 162,000 pediatric patients found a nearly tenfold increase in the odds of a repeat exacerbation following a previous one.
The economic implications are equally staggering. A 2025 study tracking nearly 90,000 working-age patients confirmed that the frequency of exacerbations is the primary driver of the disease’s economic burden. While follow-up visits represent an upfront cost, they are arguably the least expensive mechanism for preventing high-cost downstream events. Studies have shown that while the evidence for follow-up is nuanced—with some earlier research suggesting that sicker patients (who are more likely to seek follow-up) drive higher ED usage rates—recent evidence indicates that timely follow-up within 14 days is linked to a reduction in return ED visits at one year (25% vs. 28.3%).
Official Perspectives: The Gap Between Compliance and Care
While the AAF-E measure is an improvement, experts within the quality community, including those at NCQA, recognize a lingering gap: the measure strictly tracks the existence of a visit with an asthma diagnosis code, not the content of that visit.

The official guidance for the AAF-E suggests that a successful visit should include a reassessment of lung function, an evaluation of symptom resolution, a review of triggers, and the creation of a comprehensive long-term management plan. However, a health plan can technically "pass" the measure even if the provider simply refills a prescription without addressing why the patient ended up in the ED in the first place.
This creates a tension between administrative compliance and clinical efficacy. Health plans that want to drive true value must incentivize providers to go beyond the code. They must prioritize outcomes that reduce the total cost of care—an objective that is only achievable if the patient leaves the follow-up visit with a higher level of disease control and a lower risk of future recurrence.
Implications for Practice: How to Make the Visit Count
For clinicians, the new HEDIS mandate is an opportunity to revitalize the patient-provider relationship. To ensure that the 30-day window is utilized effectively, practices should consider the following strategies:
1. Reassess Control Objectively
Clinicians must move away from "How are you feeling?" as the sole diagnostic tool. Validated assessment tools, such as the Asthma Control Test (ACT), provide a standardized way to measure symptom burden that is independent of a patient’s often-subjective interpretation of their "normal."
2. The Inhaler Technique Check
It is a common clinical oversight to assume that a patient who has been on a controller medication for years knows how to use it correctly. A systematic review of 144 studies revealed that only 31% of patients use their inhaler correctly—a rate that has remained stagnant for decades. Every post-acute visit should include a "show-and-tell" session where the patient demonstrates their technique with a placebo device.
3. Digging for Triggers
If a patient arrives in the ED, something failed. Was it a viral illness? An environmental change at home? A new occupation? Or perhaps undiagnosed allergies? Given that allergic triggers are a major driver of exacerbations, clinicians should consider skin or blood testing for patients with suggestive histories, as recommended by the 2020 NAEPP guidelines.
4. Challenging the Diagnosis
In older adults or those with a history of smoking, the "asthma" diagnosis may be inaccurate. Research indicates that 25% to 50% of patients labeled with COPD have no airflow obstruction on spirometry, and many likely have undiagnosed asthma. Conversely, "asthma-COPD overlap" is present in 27% of COPD patients. If treatment is failing, it is time to reassess the diagnosis entirely, potentially through specialist referral.
Conclusion: The Path Forward
The retirement of the Asthma Medication Ratio and the implementation of the AAF-E measure represent a pivotal moment in public health quality reporting. We are moving from a world where we count pills to a world where we account for the patient’s experience.
However, the true test of this measure will not be found in data spreadsheets or HEDIS audit reports. It will be found in the reduction of urgent care volumes and the improved quality of life for millions of Americans living with asthma. For providers, the 30-day follow-up visit is no longer just a billing requirement; it is a critical window to prevent the next crisis, address the root cause, and reclaim control over a chronic condition that, when managed correctly, should not be a cause for emergency intervention. The tools are available, the mandate is clear, and the clinical responsibility is ours to accept.
